Paul M. Barr, M.D.

Paul M. Barr, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, NY 14642

Professional Bio

Paul M. Barr, M.D. is an Assistant Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Center.





Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Research Bio

Paul M. Barr, M.D. is an Assistant Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Center.



Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Awards & Honors (Local)

NIH Loan Repayment Program Award Recipient | NIH 2011
American Society of Hematology Clinical Research Training Institute 2009
NIH/NCI K12 Paul Calabresi Scholar | NIH | University Hospitals Case Medical Center, Case Western Resrve 2008
John W. Harris, MD Hematology Scholar Award | Case Western Reserve University 2006 - 2007
Chief Medical Resident | Case Western Reserve University/University Hospitals 2003 - 2004

Recent Journal Articles

Showing the 5 most recent journal articles. 25 available »

2014 Mar 1
Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P. "Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma." Journal of the National Comprehensive Cancer Network : JNCCN.. 2014 Mar 1; 12(3):323-6.
2013 Oct
Barr PM. "Flavopiridol: Judged by the company one keeps." Leukemia research.. 2013 Oct; 37(10):1187-8. Epub 2013 Jul 08.
2013 Aug
Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. "Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia." Leukemia.. 2013 Aug; 27(8):1769-73. Epub 2013 Feb 06.
2013 Feb
Barr PM. "Fffuse large B-cell lymphoma in the very elderly: the case for refining our clinical trials." Oncology (Williston Park, N.Y.). 2013 Feb; 27(2):140, 142.
2013
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013 24(12):3076-81. Epub 2013 Oct 20.

Current Appointments

Medical Director, Cancer Center Clinical Trials Office - Department of Medicine (SMD)
Assistant Professor - Department of Medicine, Hematology/Oncology (SMD) - Primary
Assistant Professor - Cancer Center

Specialties

Hematology - American Board of Internal Medicine
Medical Oncology - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine

Education

MD | Medicine | Northeastern Ohio Univs Med Sch2000
BA | Zoology | Miami University-Oxford1996

Post-Doctoral Training & Residency

Fellowship in Hematology/Oncology at University Hospitals of Cleveland07/01/2004 - 06/30/2007
Residency in Internal Medicine at University Hospitals of Cleveland07/01/2001 - 06/30/2003
Internship in Internal Medicine at University Hospitals of Cleveland07/01/2000 - 06/30/2001